Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301 [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of tazarotene foam 0.1% for acne vulgaris has completed and posted results in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• Tazarotene Foam 0.1% (tazarotene)

Snippet

Sponsor: Stiefel, a GSK Company | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2012-07-06